Biggest News Aggregation in the World
📰 Durable News

Page 67 - Durable News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Durable. Real-time updates on events, politics, business and more.

AVROBIO Announces Positive Data from Phase 1/2 Clinical Trial of Investigational Gene Therapy for Cystinosis at the ASGCT 26th Annual Meeting

All patients remain off oral cysteamine up to 36 months post gene therapy Sustained engraftment and durable reduction in leukocyte cystine levels across all patients Received positive regulatory... | May 18, 2023
United States United Kingdom Essra Ridha Los Angeles Drug Administration Exchange Commission

INFiLED to Exhibit Advanced LED Screens at InfoComm Asia 2023

SHENZHEN, China, May 10, 2023 /PRNewswire/ -- From May 24th to 26th, at InfoComm Asia 2023 held in Bangkok, Thailand, INFiLED will showcase visual solutions for xR production and out-of-home media, as well as quality LED screens applicable for various scenarios including offices, airport terminals, stages, and shopping malls. At this exhibition, one of the most anticipated of the INFiLED booth will be a small xR virtual shooting platform it built. The platform consists of a DB2.6, XII 2.6 combin...
Krung Thep Mahanakhon Infocomm Asia Queen Sirikit National Convention Center May 10 023 Prnewswire From May 24th To 26th T Infocomm Asia 2023 Held In Bangkok

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

Mendus announces positive data from the ALISON trial in ovarian cancer presented at the AACR Annual Meeting 2023

VIDIDENCEL INDUCES DURABLE VACCINE-INDUCED T-CELL RESPONSES IN THE MAJORITY OF PATIENTS Mendus AB , a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today... | April 19, 2023
United States Corey Davis Erik Manting Mario Brkulj American Association For Cancer Research University Medical Center Groningen

MorphoSys and Incyte Announce Five-Year Results of L-MIND Study Showed Prolonged, Durable Responses in Relapsed or Refractory DLBCL Patients Treated with Monjuvi® (tafasitamab-cxix)

EQS-News: MorphoSys AG / Key word: Miscellaneous MorphoSys and Incyte Announce Five-Year Results of L-MIND Study Showed Prolonged, Durable Responses in Relapsed or Refractory DLBCL... | April 16, 2023
United States University Hospital Steven Stein Tim Demuth Johannes Duell American Association For Cancer Research Annual Meeting

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science